BLIS Technologies (NZSE:BLT) Gross-Profit-to-Asset % : 78.81% (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. BLIS Technologies's annualized Gross Profit for the quarter that ended in Mar. 2024 was NZ$9.81 Mil. BLIS Technologies's average Total Assets over the quarter that ended in Mar. 2024 was NZ$12.44 Mil. Therefore, BLIS Technologies's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 78.81%.

BLIS Technologies Gross-Profit-to-Asset % Historical Data

The historical data trend for BLIS Technologies's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BLIS Technologies Gross-Profit-to-Asset % Chart

BLIS Technologies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

134.01

113.52

62.62

57.61

63.97

BLIS Technologies Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															52.52	51.68	68.59	53.81	78.81

Competitive Comparison of BLIS Technologies's Gross-Profit-to-Asset %

For the Biotechnology subindustry, BLIS Technologies's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BLIS Technologies's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's Gross-Profit-to-Asset % falls into.

BLIS Technologies Gross-Profit-to-Asset % Calculation

BLIS Technologies's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2024 )	/	( (Total Assets (A: Mar. 2023 )	+	Total Assets (A: Mar. 2024 ))	/ count )
	=	8.234	/	( (12.809	+	12.933)	/ 2 )
	=	8.234	/	12.871
	=	63.97 %

BLIS Technologies's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	9.806	/	( (11.953	+	12.933)	/ 2 )
	=	9.806	/	12.443
	=	78.81 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

BLIS Technologies Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of BLIS Technologies's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

BLIS Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016

Website

https://www.blis.co.nz

BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).